ZL 6301
Alternative Names: ZL-6301Latest Information Update: 25 Sep 2024
At a glance
- Originator MabCare Therapeutics
- Developer ZAI Lab
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours